Peter Verwaijen
Vertrieb & Marketing bei EGETIS THERAPEUTICS AB
Aktive Positionen von Peter Verwaijen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EGETIS THERAPEUTICS AB | Vertrieb & Marketing | 05.05.2022 | - |
Karriereverlauf von Peter Verwaijen
Ehemalige bekannte Positionen von Peter Verwaijen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Finanzdirektor/CFO | 17.04.2009 | - |
Glaucus Proteomics BV
 Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Comptroller/Controller/Auditor | - | - |
Statistik
International
| Niederlande | 3 |
| Schweden | 2 |
Operativ
| Comptroller/Controller/Auditor | 1 |
| Director of Finance/CFO | 1 |
| Sales & Marketing | 1 |
Sektoral
| Health Technology | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EGETIS THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Glaucus Proteomics BV
Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
- Börse
- Insiders
- Peter Verwaijen
- Erfahrung